| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Biomarin Pharmaceutical Inc.'s insiders have reduced their positions by a net 17,557 shares worth roughly $1.2M.
Classified under Biotechnology (Health Care sector), BMRN's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 214.6K | $12.03M | - | |
| CFO | 123.3K | $6.91M | - | |
| VP | 84.1K | $4.72M | - | |
| VP | 61.0K | $4.04M | - | |
| Dir | 49.4K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2024 | Bienaime Jean Jacques68 | Director | Sell | 2,000 | $86.11 | $172,223.00 | -0.4% | -8.9% | -17.9% | |
| Mar 5, 2024 | Fuchs Henry J | President, Worldwide R&D | Sell | 35,341 | $85.18 | $3,010,395.86 | -14.3% | -11.2% | -17.2% | |
| Mar 5, 2024 | Ajer Jeffrey Robert58 | EVP, Chief Commercial Officer | Sell10b5-1 | 4,000 | $87.07 | $348,280.00 | -4.1% | -11.2% | -17.2% | |
| Feb 27, 2024 | Bienaime Jean Jacques68 | Director | Sell | 1,000 | $90.35 | $90,350.00 | -0.2% | -17.9% | -24.1% | |
| Feb 9, 2024 | Bienaime Jean Jacques68 | Director | Sale+OE10b5-1 | 30,000 | $89.03 | $2,670,750.00 | -6.7% | -7.6% | -27.7% | |
| Jan 10, 2024 | Bienaime Jean Jacques68 | Director | Sale+OE10b5-1 | 20,000 | $97.29 | $1,945,700.00 | -4.5% | -7.2% | -29.7% | |
| Dec 21, 2023 | Bienaime Jean Jacques68 | Director | Sale+OE10b5-1 | 10,000 | $93.99 | $939,900.00 | -2.3% | -10.9% | -31.0% | |
| Dec 13, 2023 | Davis George Eric65 | EVP, Chief Legal Officer | Sell10b5-1 | 13,764 | $95.30 | $1,311,709.20 | -19.8% | -13.5% | -32.7% | |
| Aug 16, 2023 | Ajer Jeffrey Robert58 | EVP, Chief Commercial Officer | Sell10b5-1 | 5,000 | $90.00 | $450,000.00 | -7.6% | -5.7% | -0.9% | |
| Aug 10, 2023 | Fuchs Henry J | President, Worldwide R&D | Sell | 12,000 | $90.43 | $1,085,110.80 | -6.4% | -5.9% | -2.5% |